Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201/Xeomin versus placebo for lower limb spasticity after stroke or traumatic brain injury
2023-505810-12-00Phase 3Completed
- Sponsor
- Merz
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in lower extremity spasticity comparing Xeomin with Placebo (2 arms). Primary endpoints: Change from baseline in derived MAS ankle score, Physician-assessed GICS and 1 more. Started Sep 2019; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
lower extremity spasticity
Beyond the preview
Go deeper on 2023-505810-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505810-12-00.